A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer

Sponsor

Memorial Sloan Kettering Cancer Center (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02833233

Collaborator

Bristol-Myers Squibb (Industry)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is being done to evaluate the safety of combining two strategies called "cryoablation" and "immune therapy" in women with curable early stage breast cancer.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Procedure: Cryoablation Drug: Ipilimumab Drug: Nivolumab	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

5 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer

Actual Study Start Date :

Jun 1, 2016

Anticipated Primary Completion Date :

Jun 1, 2023

Anticipated Study Completion Date :

Jun 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cryoablation and Immune Therapy Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.	Procedure: Cryoablation Drug: Ipilimumab Drug: Nivolumab

Arm

Intervention/Treatment

Experimental: Cryoablation and Immune Therapy

Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.

Procedure: Cryoablation

Drug: Ipilimumab

Drug: Nivolumab

Outcome Measures

Primary Outcome Measures

Number of adverse events [12 weeks after ipilimumab/nivolumab administration.]
Safety will be evaluated for all treated subjects using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Women age 18 years or older
Confirmed histologic diagnosis of invasive adenocarcinoma of the breast, including MSKCC pathology confirmation
ER, PR and HER2 testing in progress (i.e. on outside or MSKCC biopsy report)
HER2-positive pathology is permitted
Operable tumor measuring ≥1.5 cm in maximal diameter
Any nodal status
Multifocal and multicentric disease is permitted
Synchronous bilateral invasive breast cancer is permitted
The tumor should be more than 5 mm from the skin
No indication of distant metastases
Breast surgery planned
Tumor amenable to cryoablation as determined by radiologist
ECOG performance status score of 0 or 1
Screening laboratory values must meet the following criteria:
White blood cells (WBCs) ≥ 2000/μL
Absolute neutrophil count (ANC) ≥ 1500/μL
Platelets ≥ 100 x 10^3/μL
Hemoglobin ≥ 11.0 g/dL
Serum creatinine ≤ 2 mg/dL (or glomerular filtration rate ≥ 40 ml/min)
AST ≤ 2.5 x upper limit of normal (ULN)
ALT ≤ 2.5 x ULN
Bilirubin within normal limits (except subjects with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL)
Negative HIV screening test
Negative screening tests for Hepatitis B and Hepatitis C. Patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigator.
Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least 3 months after the last dose of ipilimumab in such a manner that the risk of pregnancy is minimized. See below for the definition of WOCBP.
WOCBP must have a negative serum pregnancy test within 14 days prior to the first dose of ipilimumab/nivolumab
Women must not be breastfeeding
Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

Inflammatory breast cancer
Medical history and concurrent diseases
Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
Prohibited Treatments and/or Therapies
Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). However, use of corticosteroids is allowed for the treatment of immune related Adverse Events (irAEs), or adrenal insufficiency.
Any non-oncology vaccine therapy used for prevention of infectious diseases within 4 weeks prior to first dose of ipilimumab.
Prior treatment with a CD137 agonist, ipilimumab or other CTLA4 inhibitor;
Prior investigational agents within 2 weeks prior to first dose of ipilimumab;
Prior therapy with any anti-cancer agents including chemotherapy, adjuvant chemotherapy, immunosuppressive agents, surgery or radiotherapy within 2 weeks prior to first dose of ipilimumab.